We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed at $10.82 in the latest trading session, marking a -3.91% move from the prior day. This move lagged the S&P 500's daily gain of 0.41%. Elsewhere, the Dow lost 0.07%, while the tech-heavy Nasdaq added 1.11%.
Shares of the vaccine maker witnessed a gain of 11.38% over the previous month, beating the performance of the Medical sector with its gain of 1.97%, and the S&P 500's gain of 1.46%.
The investment community will be closely monitoring the performance of Novavax in its forthcoming earnings report. It is anticipated that the company will report an EPS of -$0.33, marking a 46.77% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $50.61 million, showing a 28.15% drop compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.38 per share and a revenue of $377.43 million, signifying shifts of -114.73% and -66.4%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Novavax. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 16.88% higher. Novavax is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 91, this industry ranks in the top 37% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors
Novavax (NVAX - Free Report) closed at $10.82 in the latest trading session, marking a -3.91% move from the prior day. This move lagged the S&P 500's daily gain of 0.41%. Elsewhere, the Dow lost 0.07%, while the tech-heavy Nasdaq added 1.11%.
Shares of the vaccine maker witnessed a gain of 11.38% over the previous month, beating the performance of the Medical sector with its gain of 1.97%, and the S&P 500's gain of 1.46%.
The investment community will be closely monitoring the performance of Novavax in its forthcoming earnings report. It is anticipated that the company will report an EPS of -$0.33, marking a 46.77% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $50.61 million, showing a 28.15% drop compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.38 per share and a revenue of $377.43 million, signifying shifts of -114.73% and -66.4%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Novavax. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 16.88% higher. Novavax is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 91, this industry ranks in the top 37% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.